Proteomics In-Depth Focus 2015
Posted: 21 September 2015 | David Britton (Barts Cancer Institute), Manfred Raida (National University of Singapore), Pedro Cutillas (Barts Cancer Institute)
In this Proteomics In-Depth Focus: David J. Britton & Pedro R. Cutillas from Barts Cancer Institute ask should LC-MS/MS proteomics guide targeted drug selection for cancer patients? And Manfred Raida from the National University of Singapore explains how mass spectrometry and drug development come together…
This Proteomics In-Depth Focus is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Analysis, Mass Spectrometry, Proteomics
Related organisations
Barts Cancer Institute, National University of Singapore
Related people
David Britton, Manfred Raida, Pedro Cutillas
